A detailed history of Gsa Capital Partners LLP transactions in Personalis, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 124,082 shares of PSNL stock, worth $755,659. This represents 0.05% of its overall portfolio holdings.

Number of Shares
124,082
Previous 426,876 70.93%
Holding current value
$755,659
Previous $499,000 33.87%
% of portfolio
0.05%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$1.19 - $6.34 $360,324 - $1.92 Million
-302,794 Reduced 70.93%
124,082 $668,000
Q2 2024

Aug 15, 2024

BUY
$1.17 - $1.65 $7,879 - $11,112
6,735 Added 1.6%
426,876 $499,000
Q1 2024

May 03, 2024

BUY
$1.15 - $2.19 $28,172 - $53,650
24,498 Added 6.19%
420,141 $626,000
Q4 2023

Feb 16, 2024

BUY
$0.93 - $2.35 $240,205 - $606,969
258,285 Added 188.04%
395,643 $830,000
Q3 2023

Nov 15, 2023

BUY
$1.19 - $2.36 $127,120 - $252,104
106,824 Added 349.85%
137,358 $166,000
Q2 2023

Aug 14, 2023

BUY
$1.8 - $3.19 $54,961 - $97,403
30,534 New
30,534 $57,000
Q4 2022

Feb 13, 2023

BUY
$1.78 - $3.64 $10,498 - $21,468
5,898 Added 3.91%
156,574 $310,000
Q3 2022

Nov 14, 2022

BUY
$2.89 - $5.32 $112,629 - $207,331
38,972 Added 34.89%
150,676 $448,000
Q2 2022

Aug 09, 2022

BUY
$3.27 - $8.76 $37,451 - $100,328
11,453 Added 11.42%
111,704 $385,000
Q1 2022

May 11, 2022

BUY
$7.56 - $14.3 $83,999 - $158,887
11,111 Added 12.46%
100,251 $821,000
Q4 2021

Feb 14, 2022

BUY
$12.24 - $21.25 $486,858 - $845,240
39,776 Added 80.58%
89,140 $1.27 Million
Q3 2021

Nov 12, 2021

BUY
$16.69 - $26.05 $681,753 - $1.06 Million
40,848 Added 479.66%
49,364 $950,000
Q2 2021

Aug 05, 2021

BUY
$18.15 - $27.75 $154,565 - $236,319
8,516 New
8,516 $215,000

Others Institutions Holding PSNL

About Personalis, Inc.


  • Ticker PSNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 45,918,400
  • Market Cap $280M
  • Description
  • Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or pla...
More about PSNL
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.